CVS Health Analyst Ratings
Deutsche Bank Upgrades CVS Health to Buy, Price Target at $66
Deutsche Bank Upgrades CVS Health(CVS.US) to Buy Rating, Raises Target Price to $66
CVS Health Price Target Raised to $80.00/Share From $73.00 by TD Cowen
CVS Health Is Maintained at Overweight by Piper Sandler
CVS Health Analyst Ratings
Piper Sandler Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $64
Piper Sandler Sticks to Their Buy Rating for CVS Health (CVS)
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $80
Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge: Analyst Calls 2025 A 'Primetime' Year For AI
Bernstein Lifts Price Target on CVS Health to $63 From $62
CVS Health Analyst Ratings
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $67
Truist Financial Remains a Buy on CVS Health (CVS)
Truist Lowers Price Target on CVS Health to $67 From $76, Keeps Buy Rating
Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Cuts Target Price to $57
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $75
CVS Health: Strategic Board Enhancements and Undervaluation Drive Buy Rating
CVS Health Price Target Raised to $66.00/Share From $60.00 by Wells Fargo
CVS Health Raised to Overweight From Equal-Weight by Wells Fargo